Harpoon Therapeutics (HARP) Short Interest Ratio & Short Volume

Short interest is the volume of Harpoon Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 29th, investors have sold 538,400 shares of HARP short. 4.31% of Harpoon Therapeutics' shares are currently sold short. Learn More on Harpoon Therapeutics' current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Harpoon Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.31% of Harpoon Therapeutics' floating shares are currently sold short.

Harpoon Therapeutics saw a drop in short interest during the month of February. As of February 29th, there was short interest totaling 538,400 shares, a drop of 53.6% from the previous total of 1,160,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Harpoon Therapeutics currently has issued a total of 16,932,000 shares. Some of Harpoon Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Harpoon Therapeutics currently has a public float of 12,500,000 shares.

4.31% of Harpoon Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Harpoon Therapeutics: Solid Biosciences Inc. (3.05%), Shattuck Labs, Inc. (4.40%), Corbus Pharmaceuticals Holdings, Inc. (4.58%), Nektar Therapeutics (1.32%), Celcuity Inc. (6.11%), Acrivon Therapeutics, Inc. (4.43%), Merrimack Pharmaceuticals, Inc. (4.97%), Stoke Therapeutics, Inc. (15.01%), Immutep Limited (1.43%), Theseus Pharmaceuticals, Inc. (2.63%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks.

Short selling HARP is an investing strategy that aims to generate trading profit from Harpoon Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Harpoon Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HARP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HARP, twice per month. The most recent reporting period available is February, 29 2024.